17 Breast Cancer Clinical Trials in Irvine, CA (2026)

Q: How do I join a clinical trial in Irvine?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Irvine research site will contact you.

Recruiting Breast Cancer Studies in Irvine

NCT02620852Recruiting

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended t...

Irvine, CANA100,000 participantsUniversity of California, San Francisco

View Study Details

NCT05232916Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A\*02 positive and HER2/neu positive subjects who are at high risk f...

Irvine, CAPHASE32,250 participantsGreenwich LifeSciences, Inc.

View Study Details

NCT07391774Recruiting

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast...

Irvine, CAPHASE31,978 participantsNational Cancer Institute (NCI)

View Study Details

NCT03424005Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be perform...

Irvine, CAPHASE11,132 participantsHoffmann-La Roche

View Study Details

NCT06841354Recruiting

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sac...

Irvine, CAPHASE31,000 participantsMerck Sharp & Dohme LLC

View Study Details

NCT07287098Recruiting

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

This study will include two groups of patients: Cohort 1 and Cohort 2. Cohort 1: will help researchers learn how a medicine called imlunestrant (LY3484356) affects a specific type of breast cancer. S...

Irvine, CAPHASE2600 participantsEli Lilly and Company

View Study Details

NCT06790693Recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

This study will evaluate the efficacy and safety of the combination of inavolisib plus a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) and letrozole versus placebo plus a CDK4/6i and letrozole i...

Irvine, CAPHASE3450 participantsHoffmann-La Roche

View Study Details

NCT06072612Recruiting

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physi...

Irvine, CAPHASE3404 participantsBriaCell Therapeutics Corporation

View Study Details

NCT06075953Recruiting

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effe...

Irvine, CAPHASE2400 participantsQuantumLeap Healthcare Collaborative

View Study Details

NCT04802759Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments be...

Irvine, CAPHASE1316 participantsHoffmann-La Roche

View Study Details

NCT07100106Recruiting

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participa...

Irvine, CAPHASE1285 participantsGenentech, Inc.

View Study Details

NCT05894239Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination wit...

Irvine, CAPHASE3230 participantsHoffmann-La Roche

View Study Details

NCT06369285Recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

PUMA-ALI-1201 is a randomized, dose optimization, multicenter, Phase 2 study of alisertib administered in combination with endocrine therapy in participants with pathology-confirmed HR-positive/HER2-n...

Irvine, CAPHASE2225 participantsPuma Biotechnology, Inc.

View Study Details

NCT07741968Recruiting

A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer

This clinical trial studies whether an intervention supported by technology (blended e-health intervention) works to improve fear of progression (FOP) in women with gynecologic or breast cancer. FOP i...

Irvine, CANA126 participantsCity of Hope Medical Center

View Study Details

NCT06954831Recruiting

Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer

This clinical trial tests how well ultra-hypofractionated (UF) whole breast irradiation (WBI) with lumpectomy cavity boost (CB) works in treating patients with stage I-III breast cancer. Breast conser...

Irvine, CAPHASE282 participantsCity of Hope Medical Center

View Study Details

NCT04305834Recruiting

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.

This phase IIa trial studies the side effects of abemaciclib monotherapy in treating patients age 70 years and older with hormone receptor positive, HER2 negative breast cancer that has spread to othe...

Irvine, CAPHASE243 participantsCity of Hope Medical Center

View Study Details

NCT06260033Recruiting

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

This phase II trial tests how well stereotactic body radiation therapy (SBRT) works in treating patients with estrogen receptor positive (ER +) breast cancer that has spread from where it first starte...

Irvine, CAPHASE218 participantsCity of Hope Medical Center

View Study Details

About Breast Cancer Clinical Trials in Irvine

Breast cancer is a disease in which cells in the breast grow out of control. It is the most common cancer in women worldwide and can also occur in men. Treatment options include surgery, radiation, chemotherapy, hormone therapy, and targeted therapies.

There are currently 17 breast cancer clinical trials recruiting participants in Irvine, CA. These studies are seeking a combined 109,539 participants. Research is being sponsored by University of California, San Francisco, Greenwich LifeSciences, Inc., National Cancer Institute (NCI) and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Breast Cancer Clinical Trials in Irvine — FAQ

Are there breast cancer clinical trials in Irvine?

Yes, there are 17 breast cancer clinical trials currently recruiting in Irvine, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Irvine?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Irvine research site will contact you about next steps.

Are clinical trials in Irvine free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Irvine studies also compensate for your time and travel.

What breast cancer treatments are being tested?

The 17 active trials in Irvine are testing new therapies including novel drugs, biologics, and treatment approaches for breast cancer.

Data updated October 5, 2026 from ClinicalTrials.gov